Atlas Bio
PrivateLast Round
Seed
Nov 2, 2026
Total Funding Raised
$11M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Atlas Bio operates in Healthcare & Life Sciences and is based in Basel. Its latest recorded funding round was a Seed round in November 2026.
Atlas Bio is a biotechnology company that develops an AI foundation model for in silico clinical trials to predict drug efficacy and safety in virtual patient cohorts.
Sector
Healthcare & Life Sciences
Verticals
Clinical Trials, Drug Discovery, Medical AI, Biotechnology, Synthetic Data
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Foundation
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Atlas Bio Comparables
Compare Atlas Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QuantHealth | 86% | |
| Atlas Discovery | 86% | |
| Absentia Labs | 81% |
For institutional investors. Book with your work email.
Atlas Bio Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Atlas Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Creandum | Seed |
| First Momentum Ventures | Seed |
| LEA Partners | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 2, 2026
$11M raised with Creandum as lead investor.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 2, 2026
Atlas Bio AG develops an AI foundation model trained on approximately 2 million human RNA readouts across 500,000 virtual patient profiles to simulate Phase II clinical trial efficacy and discover alternative drug indications within 12 weeks in Germany.
- receives_financingOct 27, 2026
Atlas Bio AG receives $12.5M in total funding through a $10M Seed round led by Creandum and a previously unannounced pre-Seed round led by First Momentum Ventures and LEA Partners on Oct 27th '26 in Switzerland to develop an AI foundation model for virtual drug trials.
- receives_financingOct 27, 2026
On Oct 27th '26, Atlas Bio AG receives $10M in Seed financing led by Creandum, alongside a pre-Seed round led by First Momentum Ventures and LEA Partners, bringing total funding to $12.5M to develop AI-driven virtual clinical trials in Switzerland.
For institutional investors. Book with your work email.
Atlas Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Atlas Bio's valuation, stock price, and market status.
Is Atlas Bio a public or private company?
Atlas Bio is a private company.
What is the current stock price of Atlas Bio?
Atlas Bio is a private company, so its shares have no public market price. Caplight tracks Atlas Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Atlas Bio worth (valuation)?
Valuation information for Atlas Bio is not publicly available.
Can I buy Atlas Bio stock?
Atlas Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Atlas Bio's last funding round?
Atlas Bio's most recent funding round was Seed on November 2, 2026.
Who are the main investors in Atlas Bio?
Key investors in Atlas Bio include Creandum.
Will Atlas Bio IPO soon?
No public IPO plans have been announced for Atlas Bio.
How can I track Atlas Bio secondary market activity?
Caplight tracks bids, offers, and trades in Atlas Bio's shares on secondary markets.